Literature DB >> 22917017

Pomalidomide and myeloma meningitis.

Morie A Gertz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 22917017     DOI： 10.3109/10428194.2012.723708

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

Review 1.  The next generation of novel therapies for the management of relapsed multiple myeloma.

Authors:  Wilson I Gonsalves; Paolo Milani; Daniel Derudas; Francis K Buadi
Journal:  Future Oncol       Date:  2016-08-11       Impact factor: 3.404

Review 2.  Novel agents and new therapeutic approaches for treatment of multiple myeloma.

Authors:  Roberto Ria; Antonia Reale; Angelo Vacca
Journal:  World J Methodol       Date:  2014-06-26

3.  Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.

Authors:  Yao Jiang; Jiang Wang; Darlene M Rozewski; Shamalatha Kolli; Chia-Hsien Wu; Ching-Shih Chen; Xiaoxia Yang; Craig C Hofmeister; John C Byrd; Amy J Johnson; Mitch A Phelps
Journal:  J Pharm Biomed Anal       Date:  2013-09-02       Impact factor: 3.935

4.  Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist.

Authors:  Arleigh R McCurdy; Martha Q Lacy
Journal:  Ther Adv Hematol       Date:  2013-06

Review 5.  Multiple myeloma with central nervous system relapse.

Authors:  Philip A Egan; Patrick T Elder; W Ian Deighan; Sheila J M O'Connor; H Denis Alexander
Journal:  Haematologica       Date:  2020-05-15       Impact factor: 9.941

6.  Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.

Authors:  Jason Fangusaro; Duane A Mitchell; Mehmet Kocak; Giles W Robinson; Patricia Ann Baxter; Eugene I Hwang; Jianping Huang; Arzu Onar-Thomas; Ira J Dunkel; Maryam Fouladi; Katherine E Warren
Journal:  Pediatr Blood Cancer       Date:  2020-10-07       Impact factor: 3.167
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.